FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042252004> ?p ?o ?g. }

• W2042252004 endingPage "1038" @default.
• W2042252004 startingPage "1032" @default.
• W2042252004 abstract "Purpose Mutations in KRAS and BRAF genes as well as the loss of expression of phosphatase and tensin homolog (PTEN) (deleted on chromosome 10) are associated with impaired activity of antibodies directed against epidermal growth factor receptor in patients with metastatic colorectal cancer. The predictive and prognostic value of the KRAS and BRAF point mutations as well as PTEN expression in patients with locally advanced rectal cancer (LARC) treated with cetuximab-based neoadjuvant chemoradiotherapy is unknown. Methods and Materials We have conducted phase I and II trials of the combination of weekly administration of cetuximab and irinotecan and daily doses of capecitabine in conjunction with radiotherapy (45 Gy plus 5.4 Gy) in patients with LARC (stage uT3/4 or uN+). The status of KRAS and BRAF mutations was determined with direct sequencing, and PTEN expression status was determined with immunohistochemistry testing of diagnostic tumor biopsies. Tumor regression was evaluated by using standardized regression grading, and disease-free survival (DFS) was calculated according to the Kaplan–Meier method. Results A total of 57 patients were available for analyses. A total of 31.6% of patients carried mutations in the KRAS genes. No BRAF mutations were found, while the loss of PTEN expression was observed in 9.6% of patients. Six patients achieved complete remission, and the 3-year DFS rate was 73%. No correlation was seen between tumor regression or DFS rate and a single marker or a combination of all markers. Conclusions In the present series, no BRAF mutation was detected. The presence of KRAS mutations and loss of PTEN expression were not associated with impaired response to cetuximab-based chemoradiotherapy and 3-year DFS. Mutations in KRAS and BRAF genes as well as the loss of expression of phosphatase and tensin homolog (PTEN) (deleted on chromosome 10) are associated with impaired activity of antibodies directed against epidermal growth factor receptor in patients with metastatic colorectal cancer. The predictive and prognostic value of the KRAS and BRAF point mutations as well as PTEN expression in patients with locally advanced rectal cancer (LARC) treated with cetuximab-based neoadjuvant chemoradiotherapy is unknown. We have conducted phase I and II trials of the combination of weekly administration of cetuximab and irinotecan and daily doses of capecitabine in conjunction with radiotherapy (45 Gy plus 5.4 Gy) in patients with LARC (stage uT3/4 or uN+). The status of KRAS and BRAF mutations was determined with direct sequencing, and PTEN expression status was determined with immunohistochemistry testing of diagnostic tumor biopsies. Tumor regression was evaluated by using standardized regression grading, and disease-free survival (DFS) was calculated according to the Kaplan–Meier method. A total of 57 patients were available for analyses. A total of 31.6% of patients carried mutations in the KRAS genes. No BRAF mutations were found, while the loss of PTEN expression was observed in 9.6% of patients. Six patients achieved complete remission, and the 3-year DFS rate was 73%. No correlation was seen between tumor regression or DFS rate and a single marker or a combination of all markers. In the present series, no BRAF mutation was detected. The presence of KRAS mutations and loss of PTEN expression were not associated with impaired response to cetuximab-based chemoradiotherapy and 3-year DFS." @default.
• W2042252004 created "2016-06-24" @default.
• W2042252004 creator A5001074953 @default.
• W2042252004 creator A5005989502 @default.
• W2042252004 creator A5010375570 @default.
• W2042252004 creator A5015781558 @default.
• W2042252004 creator A5029303870 @default.
• W2042252004 creator A5035964802 @default.
• W2042252004 creator A5040985262 @default.
• W2042252004 creator A5044098380 @default.
• W2042252004 creator A5046799921 @default.
• W2042252004 creator A5052177007 @default.
• W2042252004 creator A5062936656 @default.
• W2042252004 creator A5068718976 @default.
• W2042252004 date "2011-11-01" @default.
• W2042252004 modified "2023-10-18" @default.
• W2042252004 title "KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer" @default.
• W2042252004 cites W1971827763 @default.
• W2042252004 cites W1972320730 @default.
• W2042252004 cites W1999250974 @default.
• W2042252004 cites W2017233105 @default.
• W2042252004 cites W2017646046 @default.
• W2042252004 cites W2019996091 @default.
• W2042252004 cites W2038386885 @default.
• W2042252004 cites W2044658358 @default.
• W2042252004 cites W2059167706 @default.
• W2042252004 cites W2082522255 @default.
• W2042252004 cites W2097158913 @default.
• W2042252004 cites W2097709626 @default.
• W2042252004 cites W2101719692 @default.
• W2042252004 cites W2106789440 @default.
• W2042252004 cites W2110803737 @default.
• W2042252004 cites W2118613906 @default.
• W2042252004 cites W2119581553 @default.
• W2042252004 cites W2120490763 @default.
• W2042252004 cites W2124886112 @default.
• W2042252004 cites W2125229905 @default.
• W2042252004 cites W2125452425 @default.
• W2042252004 cites W2130596822 @default.
• W2042252004 cites W2131413118 @default.
• W2042252004 cites W2142564546 @default.
• W2042252004 cites W2143525722 @default.
• W2042252004 cites W2143655828 @default.
• W2042252004 cites W2152490158 @default.
• W2042252004 cites W2155384808 @default.
• W2042252004 cites W2163295338 @default.
• W2042252004 cites W2164837623 @default.
• W2042252004 cites W2165147735 @default.
• W2042252004 cites W2168280541 @default.
• W2042252004 cites W2409420104 @default.
• W2042252004 cites W4231206538 @default.
• W2042252004 cites W4385789423 @default.
• W2042252004 doi "https://doi.org/10.1016/j.ijrobp.2010.06.043" @default.
• W2042252004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20947270" @default.
• W2042252004 hasPublicationYear "2011" @default.
• W2042252004 type Work @default.
• W2042252004 sameAs 2042252004 @default.
• W2042252004 citedByCount "44" @default.
• W2042252004 countsByYear W20422520042012 @default.
• W2042252004 countsByYear W20422520042013 @default.
• W2042252004 countsByYear W20422520042014 @default.
• W2042252004 countsByYear W20422520042015 @default.
• W2042252004 countsByYear W20422520042016 @default.
• W2042252004 countsByYear W20422520042017 @default.
• W2042252004 countsByYear W20422520042019 @default.
• W2042252004 countsByYear W20422520042020 @default.
• W2042252004 countsByYear W20422520042021 @default.
• W2042252004 countsByYear W20422520042022 @default.
• W2042252004 countsByYear W20422520042023 @default.
• W2042252004 crossrefType "journal-article" @default.
• W2042252004 hasAuthorship W2042252004A5001074953 @default.
• W2042252004 hasAuthorship W2042252004A5005989502 @default.
• W2042252004 hasAuthorship W2042252004A5010375570 @default.
• W2042252004 hasAuthorship W2042252004A5015781558 @default.
• W2042252004 hasAuthorship W2042252004A5029303870 @default.
• W2042252004 hasAuthorship W2042252004A5035964802 @default.
• W2042252004 hasAuthorship W2042252004A5040985262 @default.
• W2042252004 hasAuthorship W2042252004A5044098380 @default.
• W2042252004 hasAuthorship W2042252004A5046799921 @default.
• W2042252004 hasAuthorship W2042252004A5052177007 @default.
• W2042252004 hasAuthorship W2042252004A5062936656 @default.
• W2042252004 hasAuthorship W2042252004A5068718976 @default.
• W2042252004 hasConcept C121608353 @default.
• W2042252004 hasConcept C126322002 @default.
• W2042252004 hasConcept C143998085 @default.
• W2042252004 hasConcept C18903297 @default.
• W2042252004 hasConcept C190283241 @default.
• W2042252004 hasConcept C2777286243 @default.
• W2042252004 hasConcept C2777609662 @default.
• W2042252004 hasConcept C2777909004 @default.
• W2042252004 hasConcept C2779549131 @default.
• W2042252004 hasConcept C2779998722 @default.
• W2042252004 hasConcept C2781187634 @default.
• W2042252004 hasConcept C502942594 @default.
• W2042252004 hasConcept C526805850 @default.
• W2042252004 hasConcept C55493867 @default.
• W2042252004 hasConcept C71924100 @default.
• W2042252004 hasConcept C86554907 @default.

• next